Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a
biotechnology company developing regenerative medicine therapies,
initially for trachea cancer, was featured November 27 in a television
segment and article reported by the ABC-TV affiliate in Boston (WCVB-TV).
The report, filmed at the Company’s headquarters in Holliston,
highlighted the cutting-edge science and technology involved in creating
the synthetic scaffolds and bioreactors that have been used to create
regenerated tracheas. The report noted that eight patients have received
these tracheas since the Company’s first surgery two years ago.
To watch the television segment and read the accompanying article,
please visit the following link: http://www.wcvb.com/health/labgrown-human-organs-available-for-transplants/-/9848730/23191598/-/8bmp62z/-/index.html#ixzz2m3DWNuvh
About Harvard Apparatus Regenerative Technology
Harvard Apparatus Regenerative Technology is a clinical stage
regenerative medicine company developing life-saving medical products.
Our first product, the InBreath TM Airway Transplant System,
is intended to repair a trachea that has been severely damaged by either
trachea cancer or physical trauma. None of our products are yet approved
by a government regulatory authority for marketing. On November 1, 2013,
HART was spun-off from Harvard Bioscience. We have filed a trademark
application with respect to the InBreath trademark. The trademark
“Harvard Apparatus” is used under a sublicense agreement with Harvard
Bioscience, who has licensed the right to use such trademark from
Harvard University.
Forward-Looking Statements
Some of the statements in this press release are "forward-looking" and
are made pursuant to the safe harbor provision of the Private Securities
Litigation Reform Act of 1995. These "forward-looking" statements
include statements relating to, among other things, the planned
commercialization efforts and marketing approvals of HART’s products as
well as the success thereof and the availability of a market for the
HART securities. These statements involve risks and uncertainties,
including among other things, market conditions that may cause results
to differ materially from the statements set forth in this press
release. The forward-looking statements in this press release speak only
as of the date of this press release. Harvard Apparatus Regenerative
Technology expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to such statements to reflect any
change in its expectations with regard thereto or any changes in the
events, conditions or circumstances on which any such statement is based.
Copyright Business Wire 2013